Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "ABLE"

5525 News Found

Nouryon launches sustainable technologies for cleaning ingredient at SEPAWA Congress
News | October 16, 2025

Nouryon launches sustainable technologies for cleaning ingredient at SEPAWA Congress

This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions


Maverick Simulation installs 3D anatomage table at Safdarjung Hospital
Medical Device | October 14, 2025

Maverick Simulation installs 3D anatomage table at Safdarjung Hospital

The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world


Cadila launches allergy relief tablet Dlorfast-M
News | October 13, 2025

Cadila launches allergy relief tablet Dlorfast-M

Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response


Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform
News | October 09, 2025

Lupin launches partnership program to expand global reach of PrecisionSphere injectable platform

Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles


Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets
Drug Approval | October 07, 2025

Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy


Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
Drug Approval | October 07, 2025

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ


FDA approves Alembic’s Paroxetine ER tablets
Drug Approval | September 26, 2025

FDA approves Alembic’s Paroxetine ER tablets

Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder


Lupin receives FDA tentative approval for Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets
Drug Approval | September 25, 2025

Lupin receives FDA tentative approval for Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets

Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets are indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg


Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations
News | September 25, 2025

Evonik launches MaxiPure Polysorbate 80 for injectable drug formulations

Ultra-high purity surfactant for biologics and parenteral drug formulations


Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1
Drug Approval | September 24, 2025

Zydus receives EIR for oncology injectable manufacturing facility in Ahmedabad SEZ1

The facility has been classified as Voluntary Action Indicated